The estimated Net Worth of John Kenneth Paglia is at least $1.82 Million dollars as of 4 January 2024. Mr. Paglia owns over 1,000 units of Simulations Plus stock worth over $68,803 and over the last 9 years he sold SLP stock worth over $1,548,701. In addition, he makes $200,200 as Independent Director at Simulations Plus.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Paglia SLP stock SEC Form 4 insiders trading
John has made over 6 trades of the Simulations Plus stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of SLP stock worth $43,740 on 4 January 2024.
The largest trade he's ever made was selling 17,068 units of Simulations Plus stock on 27 January 2021 worth over $1,363,392. On average, John trades about 513 units every 38 days since 2015. As of 4 January 2024 he still owns at least 2,097 units of Simulations Plus stock.
You can see the complete history of Mr. Paglia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Paglia biography
Dr. John Kenneth Paglia Ph.D. serves as Independent Director of the Company. Mr. Paglia was appointed as a Director of the Company as of December 3, 2014. Dr. Paglia holds a Ph.D. in finance, an MBA, a B.S. in finance, and is a Certified Public Accountant and Chartered Financial Analyst. In 2007 he joined the faculty of Pepperdine University, and in 2014 became Associate Dean at the Graziadio School of Business and Management at Pepperdine University. Dr. Paglia leads the design and delivery of evening and weekend business degree programs for working professionals, as well as oversees student recruitment for these programs and the school-wide marketing, communications, and public relations functions. He founded the award-winning Pepperdine Private Capital Markets Project. From 2003 to 2009, Dr. Paglia was the managing director of Paglia Consulting Group, LLC, a business valuation, financial consulting, and litigation support firm.
What is the salary of John Paglia?
As the Independent Director of Simulations Plus, the total compensation of John Paglia at Simulations Plus is $200,200. There are 10 executives at Simulations Plus getting paid more, with Shawn M. O'Connor having the highest compensation of $544,231.
How old is John Paglia?
John Paglia is 52, he's been the Independent Director of Simulations Plus since 2014. There are 10 older and 4 younger executives at Simulations Plus. The oldest executive at Simulations Plus Inc. is Walter S. Woltosz M.A.S., M.S., 76, who is the Co-Founder & Chairman.
What's John Paglia's mailing address?
John's mailing address filed with the SEC is 42505, 10th Street West, Lancaster, California, 93534, United States.
Insiders trading at Simulations Plus
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz, and Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
What does Simulations Plus do?
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
What does Simulations Plus's logo look like?
Complete history of Mr. Paglia stock trades at Simulations Plus
Simulations Plus executives and stock owners
Simulations Plus executives and other stock owners filed with the SEC include:
-
Shawn M. O'Connor,
Chief Exec. Officer -
Shawn O'Connor,
Chief Executive Officer -
William Frederick,
CFO & Sec. -
John DiBella,
President, Lancaster Division -
John Anthony DiBella M.S.,
Pres of Lancaster Division -
Thaddeus Grasela,
Senior Advisory Capacity -
John Kneisel,
Chief Financial Officer -
Jill Fiedler-Kelly M.S., MS,
Pres of Cognigen Division -
Dr. Brett A. Howell Ph.D.,
Pres of DILIsym Services, Inc -
Dr. Brett A. Howell,
Pres of DILIsym Services, Inc -
John Paglia,
Independent Director -
Daniel Weiner,
Independent Director -
David Ralph,
Independent Director -
Walter Woltosz,
Chairman of the Board -
Walter S. Woltosz M.A.S., M.S.,
Co-Founder & Chairman -
Lisa LaVange,
Independent Director -
Renee Bouche,
IR Contact Officer -
Jill Fiedler-Kelly,
President - Cognigen division -
Dr. Scott Q. Siler,
Chief Scientific Officer of DILIsym Services, Inc -
Lindsay Luke,
Exec. Director of HR -
Arlene Padron,
Corp. Director of Marketing -
Viera Lukacova Ph.D.,
Chief Scientific Officer -
Argenio David Z D,
Director -
Brett Howell,
Business Unit President -
Steven Chang,
President, Immunetrics -
William W Frederick,
CFO -
Walter Swoltosz Virginia E ...,
-
Walter S Woltosz,
Director -
Richard R Weiss,
Director -
Momoko A Beran,
Chief Financial Officer -
Harold Wayne Rosenberger,
Director -
Jeffrey A Dahlen,
VP, Research & Development -
Virginia E Woltosz,
Secretary/Treasurer -
Ronald F Creeley,
VP Marketing & Sales -
Daniel Szot,
Chief Revenue Officer -
Sharlene Evans,
Director